Skip to main content
CHENGUANG BIOTECH GROUP CO.,LTD. logo

CHENGUANG BIOTECH GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 300138 ISIN · CNE100000WC5 LEI · 655600XIK27S3214IO50 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,759 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300138

About CHENGUANG BIOTECH GROUP CO.,LTD.

https://www.cn-cg.com

CHENGUANG BIOTECH GROUP CO.,LTD. specializes in the research, development, and large-scale production of natural plant extracts. The company focuses on extracting active ingredients from botanical sources to produce natural pigments, spice extracts, essential oils, and nutritional supplements. Key products include paprika oleoresin, capsicum oleoresin, lutein, lycopene, and stevia extract. These products serve diverse applications in the food and beverage, pharmaceutical, cosmetic, and animal nutrition sectors. Utilizing advanced extraction technologies and a global raw material procurement network, the company maintains a leading position in the global market for natural colors and flavors. Its operations emphasize quality control and technological innovation to provide standardized and customized ingredient solutions for international clients.

Recent filings

Filing Released Lang Actions
关于子公司归还银行借款暨为子公司提供担保的进展公告
Regulatory Filings Classification · 80% confidence The document is a corporate announcement disclosing updates on subsidiary bank loan repayment and guarantee obligations. It does not provide financial statements, earnings data, or an actual report; rather it is a mandatory regulatory disclosure of guarantee arrangements. This fits the catch-all “Regulatory Filings” category rather than a financing report or share transaction filing.
2026-05-25 Chinese
关于子公司完成变更登记的公告
Regulatory Filings
2026-05-07 Chinese
关于向参股公司河北晨华提供财务资助的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company (晨光生物科技集团股份有限公司) regarding providing financial assistance to an associate company (河北晨华农业科技有限公司). It details the amount, terms, approvals by the board and independent directors, and related party disclosures. The document is a formal announcement of a financing activity involving capital support to a related party. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report or Interim Report, nor is it a call transcript or AGM material. The content fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities and capital structure changes. The document length is about 4541 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2026-03-30 Chinese
关于举行2025年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online performance explanation meeting (业绩说明会) for the 2025 fiscal year. It references that the full 2025 annual report has already been published on March 31, 2026, and provides details about the upcoming investor meeting scheduled for April 17, 2026. The document is short (545 characters) and serves as a notice for the event rather than containing the actual report or detailed financial data. Therefore, it is an announcement related to an investor presentation or earnings call but not the transcript or the report itself. Given the nature of the announcement about the performance explanation meeting, the best fitting category is Investor Presentation (IP).
2026-03-30 Chinese
2025年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2025 by a company. It contains detailed descriptions of the company's internal control environment, risk assessments, control activities, information and communication, and internal supervision. It also includes evaluation conclusions about the effectiveness of internal controls, both financial and non-financial, and discusses defect recognition and remediation. The document is comprehensive and contains substantive content related to internal control evaluation rather than just an announcement or summary. It is not a typical annual report, audit report, or earnings release but specifically focuses on internal control evaluation, which aligns with the category of Audit Report / Information (AR). The length (8304 characters) and detailed content confirm it is a full report rather than a brief announcement or certification. Therefore, the most appropriate classification is AR (Audit Report / Information).
2026-03-30 Chinese
关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company regarding the provision for asset impairment losses for the fiscal year 2025. It details the reasons, scope, amounts, accounting standards applied, and the impact on profits and equity. The document includes board and audit committee approvals. The length is 1945 characters, which is relatively short and the document is an announcement of the impairment provision rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report or Annual Report. It is a regulatory announcement about an accounting estimate adjustment. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.